Photodynamic diagnosis of gastrointestinal cancer using 5-aminolevulinic acid

Photodynamic diagnosis of gastrointestinal cancer using 5-aminolevulinic acid - PDD of GI cancer using 5-ALA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180148

Enrollment

150

Registered

2019-03-20

Start date

2012-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal, gastric, colorectal, hepatocellular, cholangio, pancreatic or gallbladder cancer esophageal, gastric, colorectal, hepatocellular, cholangio, pancreatic or gallbladder cancer

Interventions

administration of 5-ALA (20-60 mg/kg) prior to surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who diagnosed cancer by histological or cytological diagnosis. Patients scheduled for operation. Patients written consent has been obtained

Exclusion criteria

Exclusion criteria: porphyria patients

Design outcomes

Primary

Measure	Time frame
To assess diagnostic value of photodynamic diagnosis using 5-ALA.	—

Secondary

Measure	Time frame
To assess diagnostic value of urinary 5-ALA and its metabolite concentrations.	—

Contacts

Public ContactTakeshi Kubota

University Hospital Kyoto Prefectural University of Medicine

tkubot@koto.kpu-m.ac.jp+81-75-251-5527

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026